Short Decsription
Creative Biolabs offers CHO-K1-Tg(Human beta2 Receptor) Division-Arrested Cell which beta2 receptor stably expressed in CHO-K1 cells.
Description
CHO-K1-Tg(Human beta2 Receptor) Division-Arrested Cell was engineered to express the receptor human beta2 (NM_000024). This cell line can be used to study beta2 receptor function, signaling pathways, and potential therapeutic interventions. Dividing-arrest cells are cells that are normally kept under specific culture conditions or treated with agents that prevent cell division from being held in a non-dividing state. This can be achieved through methods such as serum starvation, chemical inhibitors of cell cycle progression, or genetic modification.
Features
Well-characterized stable cell lines;
for cell-based high-throughput screening;
Low-cost evaluation of stable cell lines or limited quantities of compounds.
Applications
beta2 receptor function, signaling pathways, and potential therapeutic interventions.
Protein Target
GPCR
Receptor Name
beta2
Receptor Family
Adrenergic
Species
Human
Parental Cell Line
CHO-K1
Transfection
Expression vector containing full-length human ADRB2 cDNA (GenBank Accession Number NM_000024) with FLAG tag sequence at N-terminus
Gene
NM_000024
Background
Norepinephrine is implicated in a wide range of physiological processes through activation of nine different G-protein-coupled receptors (α1a, α1b, α1d, α2a, α2b, α2c, β1, β2, β3). The human β2-adrenergic receptor was the first 7- transmembrane receptor for a hormone or neurotransmitter to have its crystal structure solved. It has been suggested that the β2-adrenoceptor may form homodimers as well as oligomers with other receptors. The β2-adrenoceptor mediates the actions of catecholamines in multiple tissues. They are responsible for relaxation of vascular, uterine, and airway smooth muscle, and are involved in metabolic and endocrine functions.

For Research Use Only | Not For Clinical Use

Online Inquiry
Related Products
Copyright © 2024 Creative Biolabs. All Rights Reserved.